On Feb. 24, 2025, the Food and Drug Administration did something it arguably should have done long ago: It removed the elaborate monitoring program that has governed one of psychiatry’s most important drugs, clozapine, for more than 30 years. For anyone who treats serious mental illness, this is welcome news.

But I want to say something more complicated about it, because I have spent a large part of my career prescribing this drug (or trying to) to the most vulnerable population there is: children with psychosis. The paperwork was never really the problem.

Read the rest…